Cortical Priming to Optimize Gait Rehabilitation in Stroke: a Renewal

May 8, 2026 updated by: Sangeetha Madhavan, University of Illinois at Chicago

Cortical Priming to Optimize Gait Rehabilitation: Renewal

Achieving functional ambulation post stroke continues to be a challenge for stroke survivors, clinicians, and researchers. In the effort to enhance outcomes of motor training, cortical priming using brain stimulation has emerged as a promising adjuvant to conventional rehabilitation. This project focuses on the development of a long term gait rehabilitation protocol using brain stimulation to improve walking outcomes in people with stroke. The project will also aim to understand the neural mechanisms that are associated with response to the intervention.

Study Overview

Study Type

Interventional

Enrollment (Estimated)

100

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Age greater than 18 years
  • First ever monohemispheric stroke > 3 months since onset
  • Residual hemiparetic gait deficits (e.g. abnormal gait pattern)
  • Able to walk for 5 minutes at self-paced speed. Handheld assistive device is acceptable.
  • Walking speed lesser than 1.2 m/s
  • Lower limb Fugl-Meyer Motor score between 15-30
  • At least 5 deg of ankle dorsiflexion necessary to perform the ankle-tracking task

Exclusion Criteria:

  • General exclusion criteria

    • Severe osteoporosis
    • Contracture-limiting range of motion of lower limb
    • Score of more than 2 on the Modified Ashworth Scale (indicating increased muscle tone through ankle range of motion)
    • Uncontrolled anti-spasticity medications during the study period
    • Score less than 6 on the Fugl-Meyer Sensory Assessment Scale for the Lower Limb
    • Cardiorespiratory or metabolic diseases (e.g. cardiac arrhythmia, uncontrolled hypertension or diabetes, chronic emphysema)
    • Unhealed decubiti, persistent infection
    • Significant cognitive or communication impairment (Mini-Mental State Examination (MMSE)<21), which could impede the understanding of the purpose of procedures of the study or prevent the patient from performing the ankle-tracking task.
    • Lesions involving the brainstem and cerebellum
    • Failure to pass the graded exercise stress test

TMS exclusion criteria

  • Implanted cardiac pacemaker
  • Metal implants in the head or face
  • Unexplained, recurring headaches
  • History of seizures or epilepsy
  • Currently under medication that could increase motor excitability and lower seizure threshold
  • Skull abnormalities or fractures
  • Concussion within the last 6 months
  • Currently pregnant

tDCS exclusion criteria

  • Skin hypersensitivity
  • History of contact dermatitits
  • History of allodynia and/or hyperalgesia
  • Any other skin or scalp condition that could be aggravated by tDCS

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Priming+HIISTT
Facilitatory transcranial direct current stimulation (tDCS) and ankle motor training before high intensity interval speed based treadmill training
1 mA tDCS
Visuomotor target tracking task
Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.
Sham Comparator: Sham+HIISTT
Sham tDCS before high intensity interval speed based treadmill training
Each treadmill session to include warm-up, high intensity speed-based intervals interleaved with active recovery, and cool down.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking speed with 10 meter walk test
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up
Self-selected and fastest gait speed will be measured as the average of 3 trials of the 10-m walk test (10MWT).
Change from baseline to immediately after training and baseline to 3 months follow up

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Walking spatiotemporal characteristics with GAITRite walkway
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up
Spatiotemporal parameters of walking will be assessed using a 7m long pressure sensitive mat (GAITRite walkway).
Change from baseline to immediately after training and baseline to 3 months follow up
Motor impairment with Fugl Meyer Lower Extremity Scale
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up
Lower extremity impairment will be measured using the Fugl Meyer Lower Extremity Scale (FMLE), a series of tests of movement, reflex activity, coordination/speed, sensation, and range of motion. The maximum score is 34 and a high score indicates less impairment
Change from baseline to immediately after training and baseline to 3 months follow up
Walking endurance with 6-minute walk test
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up
Walking endurance will be measured using the 6-Minute Walk test. Participants will walk as far as possible within 6 minutes.
Change from baseline to immediately after training and baseline to 3 months follow up
Ankle range of motion
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up
Ankle range of motion will be measured using a wireless electrogoniometer affixed to the ankle.
Change from baseline to immediately after training and baseline to 3 months follow up
Ankle motor control
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up
The participant will track a computer-generated sinusoidal target with ankle dorsiflexion and plantarflexion in a custom-built ankle-tracking device. Accuracy of tracking the target with ankle motion will be calculated.
Change from baseline to immediately after training and baseline to 3 months follow up
Balance with mini Balance Evaluations Systems Test (miniBESTest)
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up.
Balance will be tested with the Mini-BESTest, involving 14 different tasks to challenge balance.
Change from baseline to immediately after training and baseline to 3 months follow up.
Aerobic capacity
Time Frame: Change from baseline to immediately after training.
Cardiopulmonary exercise tests will be performed on a motorized treadmill following an individualized protocol using standard procedures. Measures relating to peak oxygen consumption (VO2 max) will be calculated.
Change from baseline to immediately after training.
Quality of Life with EuroQol-5D (EQ-5D)
Time Frame: Change from baseline to immediately after training.
Quality of life will be measured with the EuroQol-5D (EQ-5D), a questionnaire with questions designed to assess aspects of quality of life.
Change from baseline to immediately after training.
Disability with Modified Rankin Scale
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up.
Global disability will be measured with the modified Rankin Scale, a simple 0-6 rating scale.
Change from baseline to immediately after training and baseline to 3 months follow up.
Community ambulation with wearable sensors
Time Frame: Change from baseline to immediately after training.
Daily ambulation will be assessed using an accelerometer.
Change from baseline to immediately after training.
Serum brain derived neurotrophic growth factor (BDNF)
Time Frame: Change from baseline to immediately after training.
5 ml of blood will be collected from a vein in the participants' arms
Change from baseline to immediately after training.
Corticomotor excitability using transcranial magnetic stimulation
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up.
Corticomotor excitability of the paretic and non-paretic lower limb muscles such as the tibialis anterior and soleus muscle representations will be measured with single pulse transcranial magnetic stimulation (TMS).
Change from baseline to immediately after training and baseline to 3 months follow up.
Cognitive function using Mini Mental Screening Examination
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up.
30-point questionnaire used to capture orientation, attention, memory and language.
Change from baseline to immediately after training and baseline to 3 months follow up.
Depression using Patient Health Questionnaire-9 (PHQ-9)
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up.
The 9-point questionnaire is used to measure degree of depression.
Change from baseline to immediately after training and baseline to 3 months follow up.
Modified Ashworth Scale
Time Frame: Change from baseline to immediately after training and baseline to 3 months follow up.
The modified Ashworth scale is a muscle tone assessment scale used to assess the resistance experienced during passive range of motion,
Change from baseline to immediately after training and baseline to 3 months follow up.

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Sangeetha Madhavan, University of Illinois at Chicago

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 1, 2020

Primary Completion (Estimated)

December 31, 2026

Study Completion (Estimated)

August 31, 2027

Study Registration Dates

First Submitted

July 9, 2020

First Submitted That Met QC Criteria

July 15, 2020

First Posted (Actual)

July 20, 2020

Study Record Updates

Last Update Posted (Actual)

May 11, 2026

Last Update Submitted That Met QC Criteria

May 8, 2026

Last Verified

August 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Stroke

Clinical Trials on Transcranial direct current stimulation (tDCS)

Subscribe